An improved blood substitute: In vivo evaluation of its hemodynamic effects

ASAIO Journal

Volumn 42, Issue 5, 1996, Pages

  Simoni, Jan ^a   Simoni, Grace ^a   Newman, Gregory ^a   Feola, Mario ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHESIOLOGY; HEMODYNAMICS; MEDICAL PROBLEMS; MUSCLE; PATIENT TREATMENT; POLAROGRAPHIC ANALYSIS; TISSUE;

ADENOSINE; BICEPS FEMORI MUSCLE; CARDIAC INDEX; HEART RATE; HEMORRHAGIC SHOCK; MEAN ARTERIAL PRESSURE; PULSE PRESSURE; RESUSCITATIVE FLUID; STROKE VOLUME INDEX; TISSUE OXYGENATION;

BLOOD SUBSTITUTES;

BLOOD SUBSTITUTE; HEMOGLOBIN;

ANIMAL EXPERIMENT; BLOOD TRANSFUSION; CONTROLLED STUDY; HEART INDEX; HEART RATE; HEART STROKE VOLUME; HEMODYNAMIC PARAMETERS; HEMORRHAGIC SHOCK; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PULSE PRESSURE; RAT; RESUSCITATION; REVIEW; TISSUE OXYGENATION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 0030250645     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199609000-00095     Document Type: Review

References (65)

1. Klein HG: Oxygen carriers and transfusion medicine. Fifth International Symposium on Blood Substitutes. San Diego, California, March 17-20, 1993. Program and Abstracts G-1 (abstracts), 1993.
2. Scolnick AA: Transfusion medicine faces time of major challenges and changes. JAMA 268: 697-700, 1992.
3. Waymack JP, Yurt RW: The effect of blood transfusion on immune function. V. The effect of the inflammatory response to bacterial infections, J Surg Res 48: 147-153, 1990.
4. Bassett P: Blood Substitutes, Selected Growth Factors, Stem Cells and Hemoglobin Modifiers: Products, Markets and Opportunities. Drug & Market Development, Published by International Business Communications, Inc., Southborough, MA, Report No. 907, 1995.
5. Hess JR, Macdonald VW, Gomez CS, Coppes V: Increased vascular resistance with hemoglobin based oxygen carriers. Artif Cells Blood Substit Immobil Biotechnol 22: 361-372, 1994.
6. Zuck TF, Riess JG: Current status of injectable oxygen carriers. Crit Rev Clin Lab Sci 31: 295-324, 1994.
7. Marwick C: More than a trickle of interest in blood substitutes. JAMA 271: 895, 1994.
8. MacDonald VW, Winslow RM, Marini MA, Klinker MT: Coronary vasoconstrictor activity of purified and modified human hemoglobin. Biomaterials, Artificial Cells, and Immobilization Biotechnology 18: 263-282, 1990.
9. Koch T, Ducker HP, Heller A, et al: Effect of stroma-free hemoglobin solutions on pulmonary vascular resistance and mediator release in the isolated perfused rabbit lung. Shock 1: 146-152, 1994.
10. Macdonald VW, Motterlini R: Vasoconstrictor effects in isolated rabbit heart perfused with bis(3,5-dibromosalicyl)fumarate cross-linked hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 22: 565-575, 1994.
11. Kilbourn RG, De Angelo J, Bonaventura J: Inhibition of Nitric Oxide-Mediated Hypotension and Septic Shock With Iron-Containing Hemoprotein. United States Patent No. 5296466, 1994.
12. Winslow RM: Hemoglobin-Based Red Cell Substitutes. Baltimore, The John Hopkins University Press, 1992.
13. Faasses AE, Sundby SR, Panter SS, et al: Hemoglobin: a lifesaver and an oxidant how to tip the balance. Biomaterials, Artificial Cells, and Immobilization Biotechnology 16: 93-194, 1988.
14. Simoni J, Feola M, Canizaro PC: Generation of free oxygen radicals and the toxicity of hemoglobin solutions. Biomaterials, Artificial Cells, and Immobilization Biotechnology 18: 198-202, 1990.
15. Feola M, Simoni J, Canizaro PC, et al: Toxicity of polymerized hemoglobin solutions. Surg Gynecol Obstet 166: 211-222, 1988.
16. Simoni J, Simoni G, Garcia EL, et al: Protective effect of selenium on hemoglobin mediated lipid peroxidation in vivo. Artif Cells Blood Substit Immobil Biotechnol 23: 469-486, 1995.
17. Feola M, Simoni J, Canizaro PC: Polyhemoglobin Stabilized by Purine Derivatives and Glutathione. European Patent No. 0507870, 1994.
18. Feola M, Simoni J, Canizaro PC: Blood Substitute. United States Patent No. 5439882, 1995.
19. Feola M, Simoni J, Canizaro PC: Quality control of hemoglobin solutions: I. The purity of hemoglobin before modification. Artif Organs 15: 243-248, 1991.
20. Simoni J, Simoni G, Feola M: Chromatographic analysis of biopolymers distribution in "poly-hemoglobin," an intermolecularly crosslinked hemoglobin solution. Anal Chim Acta 279: 73-88, 1993.
21. Simoni J, Simoni G, Feola M, Canizaro PC: Evaluation of anionexchange liquid chromatography for purification of hemoglobin from peptides and other proteins. Anal Chim Acta 249: 169-183, 1991.
22. Simoni J, Simoni G, Lox CD, Feola M: Reaction of human endothelial cells to bovine hemoglobin solutions and tumor necrosis factor. Artif Cells Blood Substit Immobil Biotechnol 22: 777-787, 1994.
23. Hadengue A, Lee SS, Koshy A, et al: Regional blood flows by the microsphere method: reproducibility in portal hypertensive rats and influence of a portal vein catheter. Proc Soc Exp Biol Med 187: 461-468, 1988.
24. Obulouk-Darovic G: Hemodynamic Monitoring: Invasive and Noninvasive Clinical Application. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, W.B. Saunders Company, 1995, pp. 48-55.
25. Pool R: Slow going for blood substitutes. Science 250: 1655-1656, 1990.
26. Wong JF: Plunging into the world of blood substitutes is like bungee jumping. Gen Eng News 5: 28-29, 1993.
27. Hess JR: Review of modified hemoglobin research at Letterman: attempts to delineate the toxicity of cell-free tetrameric hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 23: 277-289, 1995.
28. Toda N: Mechanisms of contracting action of oxyhemoglobin in isolated monkey and dog cerebral arteries. Am J Physiol 258: H57-H63, 1990.
29. Fears W, Llave R, Jing M, et al: Contractile effects of diaspirin cross-linked hemoglobin (DCLHb™) on isolated porcine blood vessels. J Lab Clin Med 125: 762-767, 1995.
30. Barkhudaryan N, Kellermann J, Galoyan A, Lottspeich F: High molecular weight aspartic endopeptidase generates a coronaro-constrictory peptide from the β-chain of hemoglobin. FEBS Lett 329: 215-218, 1993.
31. Marshall JJ, Kontos HA: Endothelial-derived relaxing factor. A prospective from in vivo data. Hypertension 16: 371-386, 1990.
32. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991.
33. Schultz SC, Grady B, Cole F, et al: A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med 122: 301-308, 1993.
34. Mian KB, Martin W: Differential sensitivity of basal and acetylocholine-stimulated activity of nitric oxide to destruction by superoxide anion in rat aorta. Br J Pharmacol 115: 993-1000, 1995.
35. Simoni J, Simoni G, Lox CD, et al: Evidence for the direct inhibition of endothelin-1 secretion by hemoglobin in human endothelial cells. ASAIO J 41:M641-M651, 1995.
36. Liberthal W, Wolf EF, Merril EW, et al: Hemodynamic effects of stroma free hemolysates in the isolated perfused rat kidney. Life Sci 41: 2525-2533, 1987.
37. Zilletti L, Ciuffi M, Franchi-Micheli S, et al: Cyclo-oxygenase activity of hemoglobin. Methods Enzymol 231: 562-573, 1994.
38. Burhop KE, Farrel L, Nigro C, et al: Effects of intravenous infusion of diaspirin cross-linked hemoglobin (DCLHb™) on sheep. Biomaterials, Artificial Cells, and Immobilization Biotechnology 20: 581-585, 1992.
39. Saxe JM, Ledgerwood AM, Lucas CE: Principles of resuscitation, in Geller ER (eds), Shock and Resuscitation. New York, St. Louis, San Francisco, McGraw-Hill, Inc., Health Professions Division, 1993, pp. 147-179.
40. Beauchamp RD Jr, St. Clair MB, Fellell TR, et al: A critical review of the toxicity of glutaraldehyde. Crit Rev Toxicol 22: 143-174, 1992.
41. Huang-Lee LLH, Cheung DT, Nimni ME: Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived crosslinks. J Biomed Mater Res 24: 1185-1201, 1990.
42. DeLoach JR, Sheffield CL: Lipid-free bovine hemoglobin transfusion into rodents. Biomat Artif Cells Immobil Biotechnol 19: 373A, 1991.
43. Montaguti P, Melloni E, Cavalletti E: Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethyl-formamide, absolute ethanol, and benzyl alcohol in inbred mouse strains. Arzneimittelforschung 44: 566-570, 1994.
44. Feola M, Simoni J, Simoni G, et al: Nephrotoxicity of hemoglobin solutions: effect of contaminants and chemical modification. FASEB J 7: 1395, 1993.
45. Feola M, Simoni J, Angelillo R, et al: Clinical trial of a hemoglobin based blood substitute in patients with sickle cell anemia. Surg Gynecol Obstet 174: 379-386, 1992.
46. Simoni J, Simoni G, Lox CD, et al: Cytokines and PAF release from human monocytes and macrophages: effect of hemoglobin and contaminants. Artif Cells Blood Substit Immobil Biotechnol 22: 525-534, 1994.
47. Simoni J, Simoni G, Lox CD, et al: Modified Hb solution with low prooxidant potential and desired pharmacological and antiinflammatory properties, does not activate the transcription factor NF-kappa B in human vascular endothelial cells. Artif Cells Blood Substit Immobil Biotechnol 24: 429A, 1996.
48. Simoni J, Simoni G, Lox CD, et al: Immunohistochemical evaluation of adhesion molecules and von Willebrand factor expression in human coronary artery endothelial cells incubated with different hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol 24: 428A, 1996.
49. Dalay JW, Kuroda Y, Phillis JW, Shimazu H, Ui M: Physiology and Pharmacology of Adenosine Derivatives. New York, Raven Press, 1983, pp. 1-299.
50. Haynes J Jr, Obiako B, Thompson WJ, Downey J: Adenosine induced vasodilation: receptor characterization in pulmonary circulation. Am J Physiol 268: H1862-H1868, 1995.
51. Stella L, Berrino L, Maione S, et al: Cardiovascular effects of adenosine and its analogs in anesthetized rats. Life Sci 50: 755-763, 1993.
52. Thomas T, Elnayir BK, Marshall JM: Differentiation of the peripherally mediated from the centrally mediated influences of adenosine in the rat during systemic hypoxia. Exp Physiol 79: 809-822, 1994.
53. Daval JL, Nehling A, Nicolas F: Physiological and pharmacological properties of adenosine: therapeutic implications. Life Sci 49: 1435-1453, 1991.
54. Daly JW: Adenosine receptors: targets for future drug use. J Med Chem 25: 197-207, 1982.
55. Mustafa SJ, Askar AO: Evidence suggesting an Ra-type adenosine receptor in bovine coronary arteries. J Pharmacol Exp Ther 232: 49-56, 1985.
56. Kurtz A: Adenosine stimulates guanylate cyclase activity in vascular smooth muscle cells. J Biol Chem 262: 6296-6300, 1987.
57. Imai S, Nakazawa M: Role of Adenosine and Adenine Nucleotides in Biological Systems. Amsterdam, Elsevier, 1991.
58. Yamagishi T, Yaangisawa T, Satoh K, et al: Relaxant mechanism of cyclic AMP-increasing agents in porcine coronary artery. Eur J Pharmacol 251: 253-262, 1994.
59. Matsunaga T, Okumura K, Tsunoda R, et al: Role of adenosine in regulation of coronary flow in dogs with inhibited synthesis of endothelium-derived nitric oxide. Am J Physiol 270: H427-H434, 1996.
60. Maggirwar SB, Dhanraj DN, Somani SM, Ramkumar V: Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem Biophys Res Commun 201: 508-515, 1994.
61. Bouma MG, van den Wildenburg FAJM, Buurman WA: Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells, Am J Physiol 270: C522-C529, 1996.
62. Bouma MG, Stad RK, van den Wildenberg FAJM, Buurman WA: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153: 4159-4168, 1994.
63. Parmely MJ, Zhou WW, Edwards III CK, et al: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 151: 389-396, 1993.
64. Cronstein BN: Adenosine, and endogenous anti-inflammatory agent. J Appl Physiol 76: 5-13, 1994.
65. Grisham MB, Hernandez LA, Granger DN: Adenosine inhibits ischemia-reperfusion-induced leukocyte adherence and extravasation. Am J Physiol 257: H1334-H1339, 1989.